Skip to main content Accessibility help
×
Home

Predictive utility of swab screening for extended-spectrum beta-lactamase-producing organisms in selection of empiric antibiotics for Gram-negative sterile-site infections: A retrospective cohort study

  • Ian A. Brasg (a1), Marion Elligsen (a2), Nick Daneman (a1) (a3) and Derek R. MacFadden (a1)

Copyright

Corresponding author

Author for correspondence: Derek MacFadden, E-mail: derek.macfadden@mail.utoronto.ca

References

Hide All
1. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2014. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC 2015.
2. Schwaber, MJ, Carmeli, Y. Mortality and delay in effective therapy associated with extended-spectrum β-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007;60:913920.
3. Brasg, I, Elligsen, M, MacFadden, D, Daneman, N. Predictive utility of swab screening for vancomycin-resistant Enterococcus in selection of empiric antibiotics for Enterococcus sterile-site infections: a retrospective cohort study. CMAJ Open 2017;5:E632E637.
4. MacFadden, DR, Elligsen, M, Robicsek, A, Ricciuto, DR, Daneman, N. Utility of prior screening for methicillin-resistant Staphylococcus aureus in predicting resistance of S. aureus infections. Canad Med Assoc J 2013;185:E725E730.
5. Goulenok, T, Ferroni, A, Bille, E, et al. Risk factors for developing ESBL E. coli: can clinicians predict infection in patients with prior colonization? J Hosp Infect 2013;84:294299.
6. Denis, B, Lafaurie, M, Donay, J-L, et al. Prevalence, risk factors, and impact on clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteraemia: a five-year study. Int J Infect Dis 2015; 39:16.
7. Frakking, FNJ, Rottier, WC, Dorigo-Zetsma, JW, et al. Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum β-lactamase–producing bacteria. Antimicrob Agent Chemother 2013;57:30923099.
8. Van Aken, S, Lund, N, Ahl, J, Odenholt, I, Tham, J. Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum β-lactamase–producing Escherichia coli bacteraemia. Scand J Infect Dis 2014;46:753762.
9. Harris, PNA, Tambyah, PA, Lye, DC, et al. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA 2018;320:984994.

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed